Navigation Links
Amgen Announces Positive Top-Line Results From 52-Week Phase 3 DESCARTES Study Of Evolocumab (AMG 145) In Patients With High Cholesterol
Date:12/19/2013

THOUSAND OAKS, Calif., Dec. 19, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the Phase 3 DESCARTES (Durable Effect of PCSK9 Antibody CompARed wiTh PlacEbo Study) study evaluating the long-term 52-week safety and efficacy of evolocumab for the treatment of high cholesterol met its primary endpoint of percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at week 52. The mean percent reduction in LDL-C, or "bad" cholesterol, was consistent with the results observed in the 52-week analysis of the Phase 2 OSLER (Open Label Study of Long TERm Evaluation Against LDL-C) study.

Evolocumab is an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver's ability to remove LDL-C from the blood.1

The DESCARTES study evaluated safety, tolerability and efficacy in 901 patients with high LDL-C and a range of cardiovascular risk. Background lipid-lowering therapy was optimized to one of four treatment groups (diet alone; diet plus atorvastatin 10 mg; diet plus atorvastatin 80 mg; and diet plus atorvastatin 80 mg plus ezetimibe 10 mg) for individual patients based on their LDL-C and cardiovascular risk. Patients with a fasting LDL-C ≥ 75 mg/dL were then randomized to receive monthly subcutaneous evolocumab 420 mg or placebo in combination with background lipid-lowering therapy.

Evolocumab significantly reduced LDL-C, as measured by the accepted standard, preparative ultracentrifugation, from baseline at week 52 compared to placebo.  LDL-C reduction at week 12 was consistent with the long-term efficacy at week 52.

Safety was balanced across treatment groups. The most common adverse events (> 5 percent
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Amgen Announces 2014 First Quarter Dividend
2. Amgen To Present At The Oppenheimer 24th Annual Healthcare Conference
3. Amgen To Webcast Investor Meeting At Upcoming American Heart Association Scientific Sessions 2013
4. Amgens Third Quarter 2013 Revenues Increased 10 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 16 Percent To $1.94
5. Amgen Acquires Filgrastim Franchise Rights From Roche In 100 Markets
6. Amgen Successfully Completes Onyx Pharmaceuticals Tender Offer
7. Amgen and Onyx Pharmaceuticals Announce Early Termination of HSR Waiting Period for Amgens Acquisition of Onyx
8. Amgen And Cytokinetics Announce The First Presentation Of Data From Phase 2 ATOMIC-AHF Study Of Omecamtiv Mecarbil
9. Amgen To Participate At Citis 8th Annual Biotech Conference
10. Healthcare Briefing - Leading Medical Companies in the News: Bio-Solutions, Catalyst Pharmaceutical, MannKind, Amgen, Accuray
11. Amgen to Highlight New Data at Upcoming ESC Congress 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... BOSTON and NOTTINGHAM, England ... CBRX ) today announced that its subsidiary, ... to Clinical Trials platform at the annual CPhI/ICSE Worldwide ... which aims to support companies with the rapid development ... The new enabling technologies screening platform, which incorporates the ...
(Date:10/1/2014)... and NEW YORK , October 1, 2014 ... Organization (CRO) and service provider for the medical industries, announced today ... offices in New York City . genae Americas ... is strategically centered in one of the highest concentrations ... said Philippe Kassab , President at genae Americas. "The expansion ...
(Date:10/1/2014)... Oct. 1, 2014 Trovagene, Inc., (NASDAQ: ... today that Eli Diamond , MD, Assistant ... (MSK), presented clinical data from an ongoing study ... platform for the determination of oncogene mutational status ... The results were presented to both treating physicians ...
Breaking Medicine Technology:Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 2Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 3genae Opens Offices in New York City 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 4
... CHICAGO, Nov. 16, 2010 New results from ... at the American Heart Association (AHA) Scientific Sessions ... (prasugrel) prior to coronary artery bypass graft surgery ... to patients treated with Plavix® (clopidogrel) (2.3 percent ...
... RIDGE, N.J., Nov. 16, 2010 Regado Biosciences, Inc., ... aptamers with active control agents, announced that Thomas J. ... abstract at the AHA Scientific Sessions meeting on November ... The abstract, entitled "RB006, a Direct Factor ...
Cached Medicine Technology:Mortality Data Presented for Patients Treated with Efient®/Effient® (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery 2Mortality Data Presented for Patients Treated with Efient®/Effient® (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery 3Mortality Data Presented for Patients Treated with Efient®/Effient® (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery 4Mortality Data Presented for Patients Treated with Efient®/Effient® (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery 5Mortality Data Presented for Patients Treated with Efient®/Effient® (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery 6Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting 2Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting 3Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting 4
(Date:10/1/2014)... (PRWEB) October 01, 2014 Familylifeinsurancequotes.org ... find life insurance for senior citizens. , Senior ... Agencies will now sell coverage to seniors who are ... can be purchased without taking a medical examination. , ... purchased online and senior clients can qualify. Having life ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new blog post ... for smokers. , Smoking will always have a negative ... the best method to find affordable coverage. Insurance brokerage ... coverage. , Whole life insurance premiums will be ... the coverage is permanent, the initial rates are ...
(Date:10/1/2014)... 01, 2014 Farmington Company today ... redefined mission and visual identity helping brokers, consultants ... with them to create greater benefit communication synergies. ... focuses on empowering customers to better leverage Farmington ... crown jewel of the rebrand is the refreshed ...
(Date:10/1/2014)... 2014 Between 23 million and 50 ... according to figures from the National Institutes of Health ... and many of them have something else in common: ... celiac disease. Gluten Free Therapeutics, makers of CeliVites ... celiac disease by publishing a series of blog posts ...
(Date:10/1/2014)... Toronto, Canada (PRWEB) October 01, 2014 ... hair removal and skin rejuvenating destination of choice, is ... run from October through to December. , “We’re doing ... access as possible to our top skin clinic in ... Clinic. “We do so much at Anti Aging Clinic, ...
Breaking Medicine News(10 mins):Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2
... JACKSONVILLE, Fla., July 7 Blue Cross and Blue ... health care providers in Broward, Charlotte, Hernando, Pasco, and ... plan. This affordable option features a community-based network, allowing ... on services and premiums, without sacrificing quality coverage. ...
... LISLE, IL, July 7 /PRNewswire-FirstCall/ - SXC Health Solutions ... , TSX: SXC), a leading provider of technology and ... PBM unit has been awarded an 18-month contract, with ... services to Presbyterian Health Plan, a health maintenance organization ...
... Drug Study Dosages to Address Bone Density, Heart Health and Joint ... Inc. (Nasdaq: NXXI ), a developer and marketer of ... health, enhance memory and address chronic joint pain today announced the ... PRESCRIPTIX (TM). , , The ...
... Pharmasset, Inc. (Nasdaq: VRUS ) announced today ... candidate from two series of purine analogs for the ... is a proprietary nucleotide analog polymerase inhibitor of HCV ... of an Investigational New Drug (IND) application with the ...
... Blood Education , , BROOKEVILLE, Md., July 7 Expectant ... study published in the Journal of ... e . In fact, of the expectant mothers in the ... 74 percent considered themselves minimally informed. Yet, the Institute of ...
... simple, effective alternative to tubal ligation , , ... the Company) (Nasdaq: HOLX ), a leading ... systems and surgical products dedicated to serving the healthcare ... Drug Administration (FDA) has approved the Company,s premarket approval ...
Cached Medicine News:Health News:Blue Cross and Blue Shield of Florida Expands Low-Cost 'BlueSelect' Health Plan to Five Florida Counties 2Health News:SXC Health Solutions announces PBM contract with Presbyterian Health Plan 2Health News:SXC Health Solutions announces PBM contract with Presbyterian Health Plan 3Health News:SXC Health Solutions announces PBM contract with Presbyterian Health Plan 4Health News:Nutrition 21 Launches New Innovative PRESCRIPTIX(TM) Nutraceuticals Product Line 2Health News:Nutrition 21 Launches New Innovative PRESCRIPTIX(TM) Nutraceuticals Product Line 3Health News:Nutrition 21 Launches New Innovative PRESCRIPTIX(TM) Nutraceuticals Product Line 4Health News:Nutrition 21 Launches New Innovative PRESCRIPTIX(TM) Nutraceuticals Product Line 5Health News:Pharmasset Nominates PSI-938 as a New Nucleotide Analog Inhibitor of Hepatitis C for Preclinical Development 2Health News:Pharmasset Nominates PSI-938 as a New Nucleotide Analog Inhibitor of Hepatitis C for Preclinical Development 3Health News:Parent's Guide to Cord Blood Foundation Introduces New Brochure During Cord Blood Awareness Month to Address Critical Education Gap 2Health News:Parent's Guide to Cord Blood Foundation Introduces New Brochure During Cord Blood Awareness Month to Address Critical Education Gap 3Health News:Video: FDA Approves Hologic's Adiana(R) Permanent Contraception System 2Health News:Video: FDA Approves Hologic's Adiana(R) Permanent Contraception System 3Health News:Video: FDA Approves Hologic's Adiana(R) Permanent Contraception System 4Health News:Video: FDA Approves Hologic's Adiana(R) Permanent Contraception System 5
... Agilis Steerable Introducer helps physicians ... right or left atrium. With ... tip, and radiopaque tip marker, ... the agility and stability needed ...
... 70 RF Generator introduces maximum ... every day, in every ablation ... and the CARTO EP Navigation ... Catheter provide clinicians with a ...
The Microny pacemakers are among the smallest devices in the world. The Microny II SR+ pacemaker is the world's smallest, single-chamber rate-responsive pulse generator. The Microny pacemakers featur...
... family of pacemakers features several ... truly automatic devices in today's ... unparalleled combination of automated features ... builds on the popular and ...
Medicine Products: